PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a dismal prognosis which is, among others, due to a lack of suitable biomarkers and therapeutic targets. Previously, basic gene expression analysis methods have been used for their identification, but recently new algorithms have been developed allowing more comprehensive data analyses. Among them, weighted gene co-expression network analysis (WGCNA) has already been applied to several cancer types with promising results. METHODS: We applied WGCNA to miRNA expression data from PDAC patients. Specifically, we processed microarray-based expression data of 2555 miRNAs in serum from 100 PDAC patients and 150 healthy subjects. We identified network modules o...
Background: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive malignancy with a 5-year su...
Background: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive malignancy with a 5-year su...
Background: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive malignancy with a 5-year su...
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a dismal pro...
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a dismal pro...
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a dismal pro...
Purpose: MicroRNAs (miRNA) have potential as diagnostic and prognostic biomarkers and as therapeutic...
OBJECTIVE: The aim of the study was to perform mRNA-miRNA regulatory network analyses to identify a ...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common type of PCa with 2-9% 5-year ...
OBJECTIVES: Accurate peripheral markers for the diagnosis of pancreatic ductal adenocarcinoma (PDAC)...
Xiwen Liao,1 Xiangkun Wang,1 Ketuan Huang,1 Chengkun Yang,1 Tingdong Yu,1 Chuangye Han,1 Guangzhi Zh...
Purpose: Despite extensive biological and clinical studies, including comprehensive genomic and tran...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is associated with a very poor prognosis. Therefore...
Background: Tumor stage predicts pancreatic cancer (PDAC) prognosis, but prolonged and short surviva...
Background: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive malignancy with a 5-year su...
Background: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive malignancy with a 5-year su...
Background: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive malignancy with a 5-year su...
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a dismal pro...
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a dismal pro...
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a dismal pro...
Purpose: MicroRNAs (miRNA) have potential as diagnostic and prognostic biomarkers and as therapeutic...
OBJECTIVE: The aim of the study was to perform mRNA-miRNA regulatory network analyses to identify a ...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common type of PCa with 2-9% 5-year ...
OBJECTIVES: Accurate peripheral markers for the diagnosis of pancreatic ductal adenocarcinoma (PDAC)...
Xiwen Liao,1 Xiangkun Wang,1 Ketuan Huang,1 Chengkun Yang,1 Tingdong Yu,1 Chuangye Han,1 Guangzhi Zh...
Purpose: Despite extensive biological and clinical studies, including comprehensive genomic and tran...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is associated with a very poor prognosis. Therefore...
Background: Tumor stage predicts pancreatic cancer (PDAC) prognosis, but prolonged and short surviva...
Background: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive malignancy with a 5-year su...
Background: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive malignancy with a 5-year su...
Background: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive malignancy with a 5-year su...